Anthem Biosciences shares rose 9% as the company reported a strong recovery in the September 2026 quarter. Revenue grew 7.9% to ₹5,940 million with record-high EBITDA margins of 50.6%, helping the firm overcome a slow start to the fiscal year.
Anthem Biosciences shares saw a 9 percent increase following the company's strong financial performance in the second quarter of fiscal 2027. The company reported revenue of ₹5,940 million, marking a 7.9 percent increase compared to the same period last year. This result signals a clear recovery after the company faced a 22.6 percent revenue contraction in the first quarter of the year. Profit after tax also improved, reaching ₹2,115 million, which is a 21.9 percent rise year-on-year.
The most notable highlight for investors was the company's profitability. Anthem Biosciences achieved record-high EBITDA margins of 50.6 percent for the quarter. This margin expansion was largely supported by its core contract research, development, and manufacturing organization segment, which remains the primary driver, contributing 85.7 percent of the company's total revenue. By focusing on a favorable product mix, the company managed to protect its profitability despite the earlier operational challenges seen in the fiscal year.
Anthem Biosciences is also progressing with its commercial pipeline. The company has now successfully commercialized 15 products. The recent addition of a phase III molecule into the commercialization stage is a key development, as it helps the company scale its production. Analysts often view the company’s role as a sole supplier for its more recent commercialized products—specifically those launched since the start of fiscal 2026—as a key business advantage that supports long-term volume growth.
While the recent numbers are positive, investors are also considering the company's valuation. Anthem Biosciences is currently trading at approximately 55 times one-year forward earnings, placing it at a similar valuation level to industry peer Divi's Laboratories. This premium valuation suggests that the market expects consistent growth, and any failure to maintain top-line momentum could be closely watched by investors.
There are also risks to keep in mind. The company relies heavily on smaller biotech clients for a significant portion of its business. These smaller firms are often targets for acquisitions by larger companies, which can create uncertainty regarding future contract stability. Additionally, the industry is capital-intensive, requiring steady investment in new areas like peptides and other complex molecules to remain competitive. Given the company’s low debt-to-equity ratio of approximately 0.02, it maintains a healthy balance sheet, but its performance will likely remain tied to global pharmaceutical spending cycles and the regulatory success of its drug pipeline.
Investors may continue to track the management's ability to maintain high margins in the coming quarters and monitor the progress of new molecules in the development pipeline.